Comparing KTP and CO₂ laser excision for recurrent respiratory papillomatosis: A systematic review

Jimin Yang MD 1 | Zhongcheng Xie MD 2 | Barnabas C. Seyler PhD 3

1Department of Otolaryngology, Head and Neck Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China
2Department of Anatomy, Hengyang Medical School, University of South China, Hengyang, Hunan, China
3Department of Environment, College of Architecture and Environment, Sichuan University, Chengdu, Sichuan, China

Correspondence
Barnabas C. Seyler, Department of Environment, College of Architecture and Environment, Sichuan University, No. 24 South Section 1, Yihuan Road, Chengdu 610065, Sichuan, China. Email: bseyler@scu.edu.cn

Abstract
Objective: The CO₂ laser and 532 nm potassium titanyl phosphate (KTP) laser have been applied to treat recurrent respiratory papillomatosis (RRP). This systematic review sought to compare outcome differences between these two methods.

Data Sources: Embase, Web of Science, PubMed, and the Cochrane Library.

Review Methods: CO₂ laser and KTP laser studies were obtained by keyword searches of four authoritative medical databases. Articles were screened and retained when conforming to inclusion criteria. The primary outcome was cure rate; the secondary outcomes were recurrence, death, remission, clearance, and human papillomavirus (HPV)-detected rates, as well as laser effectiveness rates. Postoperative complications rate was the safety outcome measure. All outcomes were summarized within the CO₂ and KTP groups, with results statistically compared (p < .05).

Results: Overall, the cure rates were 87.25% (KTP group) and 75.98% (CO₂ group; p < .05). Complication rates significantly differed between the KTP (2.32%) and CO₂ (17.71%) groups (p < .0001). There was a relatively higher but not significant difference in the recurrence rates between the CO₂ (18.6%) and KTP (10.87%) groups (p = .1595). The CO₂ group remission rate was considerably lower (38.9%) than the KTP group (88.46%, p < .0001). HPV-detected and clearance rates were only reported for the CO₂ group. The bias risks were 13.1 ± 1.45 (CO₂) and 13.6 ± 1.52 (KTP) for the two groups, indicating evidence was of fair quality.

Conclusion: Overall, KTP laser excision showed significantly better postoperative clinical outcomes than the CO₂ laser, with a lower failure rate. Available fair-quality evidence suggests KTP laser excision might be better for treating RRP. Nevertheless, more high-quality randomized controlled studies are needed to compare these two surgical techniques, particularly in terms of reporting functional data such as vocal outcomes.

KEYWORDS
532 nm potassium titanyl phosphate laser, CO₂ laser, laryngeal papillomatosis, recurrent respiratory papillomatosis, systematic review

Jimin Yang and Zhongcheng Xie contributed equally to this study.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2022 The Authors. Laryngoscope Investigative Otolaryngology published by Wiley Periodicals LLC on behalf of The Triological Society.
Laryngeal papillomatosis (LP) is a benign cell tumor that can afflict the whole respiratory papillomatosis tract and upper digestive tract. It is also termed recurrent respiratory papillomatosis (RRP) due to its high-frequency, postoperative recurrence rate which requires multiple surgeries overtime. In general, RRP can be divided into juvenile- and adult-onset RRP (AoRRP) based on age of onset. The reported incidence rates are 0.17 and 0.54 per 100,000 people for juvenile- and AoRRP, respectively. Like many abnormal exophytic projections, one of RRP’s morphological characteristics consists of a center of connective tissue covered by squamous epithelium. Although benign, RRP is chronic and can have a significant influence on quality of life due to airway obstruction, hoarseness, financial impact from multiple operations, and scarring, as well as the rare possibility of malignant transformation.

Currently, there is no cure or definitive treatment for RRP available, with clinical management of RRP being primarily dependent on repeated surgical resections with careful preservation of relatively normal tissues based on the surgeon’s experience. Moreover, the clinical treatment for RRP is still frustrating due to unpredictable courses, a high recurrence tendency, and intractable complications. Effective control of complications is one of the main treatment targets, which is also an important criterion for evaluating cure methods. Surgical excision in the operating room under general anesthesia is the traditional management method. Powered by advanced technologies, a direct laryngoscopic approach began in the 20th century. Afterward, with the development of the carbon dioxide (CO2) laser in the 1960s, it quickly became popular in laryngology, but multiple complications (e.g., thermal injuries) have significantly affected its application. Subsequently, in 2001, the 585-nm pulsed dye laser (PDL) was introduced to manage RRP with a fiber delivery system and merit-absorbable energy. However, bleeding caused by PDL and its extremely short pulse width prevented the further application of this technology. In recent years, adjuvant antiviral drugs have been administrated and studied for potential therapeutic applications, but their therapeutic effects have yet to be confirmed.

In the past few years, photothermolysis lasers, such as the 532-nm potassium titanyl phosphate (KTP) laser, have been widely applied in office-based laryngeal surgical procedures. Many studies have reported successful treatment of multiple vocal diseases, such as papilloma, varix, polyps, Reinke edema, vocal process granuloma, ectasia, and glottal dysplasia. The angiolytic properties of KTP shrink lesions through photothermolysis and the laser energy can be absorbed by hemoglobin. Given these advantages, the KTP laser could be the future of RRP treatment. However, the CO2 laser remains the first choice for treating RRP by most hospitals in China due to the lack of comparative studies or consensus on which laser is better for RRP therapy.

Therefore, seeking to address this research gap, this systematic review evaluates and compares the cure, complications, and recurrence rates of CO2 and KTP laser treatments for RRP. We hypothesized that KTP laser yields better outcomes than CO2 laser for RRP treatment, having similar cure but lower complications rates.
human papillomavirus (HPV)-detected rates, as well as the laser effectiveness rate (e.g., tumor remission rate, >50%, or <50%). The postoperative complications rate was the safety outcome measure.

2.5 | Risk of bias/quality assessment

Due to the abundance of non-randomized studies in the included literature, two reviewers (JY and ZX) critically appraised (independently) all eligible studies against the Methodological Index for Nonrandomized Studies (MINORS) to assess their quality. A senior reviewer (ZL) made the final assessment decision when consensus could not be achieved. The MINORS instrument contains 12 items (Supporting Information S3): eight for noncomparative studies with an additional four for comparative studies. A score of 0 (not reported), 1 (reported but inadequate), or 2 (reported and adequate) was given for each item, resulting in an ideal maximum score of 24 for comparative studies and 16 for noncomparative studies. For non-randomized studies, the methodologic quality was assessed as follows: 0–5, very low quality of evidence; 6–10, low quality; 11–15, fair quality; 16, good quality. The outcomes of the risk of bias and quality assessment provided the confidence level for the conclusions drawn in this review.

2.6 | Data synthesis and analysis

In this study, we analyzed the following characteristics: number of patients, study design, EL, study quality, and outcomes used for the evaluation of the surgery/treatment effectiveness. Demographic and clinical outcome data could not be presented as mean ± standard deviation due to the lack of available data in most studies. Thus, we collected and calculated the number of various rates from studies, such as cure rate (e.g., no papilloma for 5 years33), and gained the overall rates of KTP/CO2 laser therapy for RRP to compare their therapeutic effects. The p-value for a continuous variable was calculated using a t-test, and Fisher exact test was conducted for a categorical variable. A p-value < .05 was considered statistically significant in this study. To further assess the robustness of the complete primary outcome results, sample size was calculated based on the cure rate at the final follow-up. By conducting a two-tail t-test of 80% power (1 – b) and a .05 significance level using G power software, an estimated sample size of 58 patients per group was required. When a published work lacked sufficient detail, we attempted to contact the authors of those studies to acquire the necessary information.

3 | RESULTS

3.1 | Search results

We identified 283 unique English abstracts. After assessing these abstracts for relevance, 51 articles were read in full (written in English, Chinese, Spanish, and German) and 15 passed all inclusion criteria (Figure 1).

3.2 | Description of studies and study characteristics

The 15 studies passing all inclusion criteria were published between 1982 and 2020 (Table 1). Of these, 12 were published in English, 2 were published in Chinese, and 1 was published in Spanish. Five studies were in the KTP group and 10 were in the CO2 group. These studies involved a total of 614 RRP patients (all sampled from outpatient departments) receiving 2120 laser surgeries, including 102 KTP cases and 512 CO2 cases. There were eight retrospective studies with only two prospective works in the CO2 group, whereas the KTP group contained two retrospective and three prospective studies.

Furthermore, the patient populations differed by study, with most studies recruiting patients having recurrent laryngeal/respiratory papillomatosis, whereas others included inverted papilloma or juvenile-onset RRP (Table 1). Note, we included patients with variable locations of papilloma expression (e.g., oral, interpharyngeal) because the pathological states and laser treatments of these patients were similar and thereby sufficient consistent for inclusion. All studies included both males and females, with a higher percentage of males for both groups (KTP, 65.61%; CO2, 66.25%), but there was no significant difference by sex between the two groups (p > .05; Table 2). However, there was a significant difference between groups for average age before surgery (p < .001; Table 2). In addition, sample sizes per study ranged between just three and 244 (median 39), with sample sizes differing for studies in the CO2 (n = 3–222) and the KTP group (9–39). The ELs of all studies were classified at level IV.

3.3 | Surgical techniques

The most important point for surgical techniques was laser setting. We found that 11 studies reported the relevant laser setting information, whereas the other four did not. Additionally, laser settings were inconsistent between studies. In the CO2 group, the laser energy setting ranged widely between 2 and 30 W reported across seven studies, while the laser frequency ranged between 100 and 300 Hz as reported by two studies. As for the KTP laser, the energy setting fell within a narrower range of just 6–8 W, which is more accurate compared to the reported CO2 laser energy settings across studies. Moreover, the KTP laser frequency was 2 Hz reported by two studies. Furthermore, most CO2 laser excision surgeries for RRP were conducted in the operation room under general anesthesia, while the majority of KTP laser excision surgeries were performed using local anesthesia.

3.4 | Indications and contradictions

All studies in this review explicitly reported that patients were diagnosed with LP or RRP, which was confirmed by pathological specimens and treated with CO2 laser/KTP laser excision. However,
Contradictions varied from study to study. Patients treated with adjunctive therapies, such as the HPV vaccine, were excluded from this study. In addition, serious cases with systemic metastases, such as in the lung, were also excluded. Moreover, patients treated not only with CO₂ laser/KTP laser but also treated at the same time point with other techniques, such as PDL laser and microblade excision, were not included. Age and gender were not limited in scope.

### 3.5 Clinical outcomes

Overall, the cure rates were significantly different between the two groups \( p = .0127 \), being higher for the KTP group (87.25%) than the CO₂ group (75.98%; Table 3). Although the recurrence rate of the CO₂ group (18.63%) was relatively higher than the KTP group (10.87%), the difference was not significant \( p = .1595 \). However, the remission rate of the CO₂ group (38.9%) was significantly lower than that of the KTP group (88.46%, \( p < .0001 \)). Other clinical outcomes, such as death, clearance, and HPV-detected rates, as well as laser effectiveness rate, could not be compared between the two groups in this study due to these parameters being rarely reported in both groups. Yet, the HPV-detected rate in the CO₂ group was 75.86% while the clearance rate was low (9.88%).

### 3.6 Complications rates

The complications rates were just 2.32% (2/86) in the KTP group, but 17.71% (88 of 497) in the CO₂ group (Table 3), being significantly different between the two groups \( p < .0001 \). In the KTP group, only two complications were reported, with webbing formed in front of the vocal fissure, causing hoarseness but not affecting breathing. Yet, for the CO₂ laser group, a greater number of complications occurred, including mucosal tears, tooth injuries, laryngeal edemas, scarring, stenosis, and web formation (most were anterior glottic webs), and delayed soft tissue complications (i.e., functionally debilitating scar formation with consecutive voice disorders or airway stenosis). These complications depended on the
| Authors (year) | EL Characteristics | Study type | Lesions | Laser settings | Outcomes | Results | Key findings |
|---------------|-------------------|------------|---------|----------------|----------|---------|--------------|
| **CO₂ laser studies** | | | | | | | |
| **Castillo et al. (2010)** | IV | N/proc: 29/NA | Retrospective | Laryngeal papillomatosis | 3–6 W continuous power | Complications: | \( n = 3/29 \) (10.4%) | Papillomatosis is characterized as a pathology with an unpredictable course and low probability of malignancy. \( n = 22/29 \) (75.8%); Mainly HPV6 and HPV11 | |
| | | Age: 14 months–84 years old | | | 100–200 Hz repetition rate | HPV detected | \( n = 22/29 \) (75.8%) | | |
| | | Gender: 10F/19M | | | | Recurrence | \( n = 13/29 \) (44.8%) | | |
| | | | | | Remission (no recurrence occurred within two months) | \( n = 6/29 \) (20.7%) | | |
| | | | | | Clearance (no recurrence occurred within 3 years) | \( n = 10/29 \) (34.5%) | | |
| | | | | | Cure (no recurrence occurred within 5 years) | \( n = 12/29 \) (41.3%) | | |
| **Dedo et al. (1982)** | IV | N/proc: 109/548 | Retrospective | Laryngeal papillomatosis | NA | Complications: acute upper airway obstruction | \( n = 2 \) (1.8%) | Treatment of LP with \( n = 9 \) (8.1%) | |
| | | Age: NA | | | | Complications: anterior glottic webbing | | Podophyllum painting represents a clear advance over traditional mechanical methods of papilloma removal when considering voice quality, remission rate, and especially incidence of complications and occurrences of death. | |
| | | Gender: 43F/66M | | | | Remission | \( n = 45 \) (41.3%) | | |
| | | | | | Malignant degeneration | \( n = 3 \) (2.7%) | | |
| | | | | | Death | \( n = 0 \) (0%) | | |
| **Dedo et al. (2001)** | IV | N/proc: 244/548 | Retrospective | Respiratory papillomas | 20 W continuous power | Complications: anterior glottic webbing | \( n = 68 \) (27%) | A true cure with elimination of all human papilloma viruses (particularly types 6 and 11) will not be achieved until a uniformly effective vaccine or antiviral and immunomodulating agents are developed. | |
| | | Age: NA | | | 0.2 s to continuous exposure time | | | |
| | | Gender: 81F/163M | | | 1–2 mm spot size | | | |
| Authors (year) | EL Characteristics | Study type | Lesions | Laser settings | Outcomes | Results | Key findings |
|---------------|--------------------|------------|---------|----------------|----------|---------|-------------|
| Holler et al. (2009) | IV N/proc: 6/90 Age: 3–17 years old Gender: 6M | Prospective | Juvenile-onset recurrent respiratory papillomastosis | NA | Jitter | 4.57% | The data demonstrate a correlation of worsening voice quality with increased exposure to the CO2 laser. |
| Koji et al. (2019) | IV N/proc: 9/14 Age: 30–56 years old Gender: 5 M/4F | Prospective validation | Recurrent respiratory papillomastosis | 2–3 W continuous or super pulse power | Recurrence | n = 3/9 (33.3%) | CO2 TNFLS is feasible as an in-office surgery for patients with laryngopharyngeal pathologies. The therapeutic outcome is as expected with the advantages of low patient burden and ease of repetition. |
| Hu et al. (2017) | IV N/proc: 6/10 Age: NA Gender: NA | Retrospective | Recurrent respiratory papillomastosis | 5 W power in super pulse with 0.05 s on and 0.01 s off | Complications | n = 0/10 | With meticulous patient selection, office-based laryngeal surgery performed using a CO2 laser appears to be a feasible treatment option for various types of vocal lesions. |
| Preuss et al. (2007) | IV N/proc: 64/137 Age: NA Gender: NA | Retrospective | Recurrent respiratory papillomastosis | 25 W | Complications: glottic webs, scar | n = 4/64 (6%) | Laser microsurgery is the preferential treatment modality due to the low rate of severe scarring and a lower tracheostomy rate as compared with laryngeal microsurgery with cold instruments. |
| Robb (1987) | IV N/proc: 5/11 Age: 2.5–23 years old Gender: 4F/7M | Retrospective | Recurrent laryngeal papilloma | 10–30 W, intermittent or pulsed | Complications: Remission (more than 1 year) Intractable airway obstruction | n = 0/11 n = 5/11 n = 2/11 | Compared to other modalities, laser offers the ability to treat frequently the pediatric larynx, with little risk of postoperative edema or bleeding, reduced hospital in-patient stays, and only mild discomfort. |
| Authors (year) | EL Characteristics | Study type | Lesions | Laser settings | Outcomes | Results | Key findings |
|---------------|----------------------|------------|---------|----------------|----------|---------|--------------|
| Saleh (1992)  | IV N/proc: 3/NA Age: 1–7 years old Gender: NA | Retrospective | Recurrent laryngeal papillomatosis | 8–10 W power | Complications | $n = 0/3$ | NA |
| Mattot et al. (1990) | IV N/proc: 37/595 Age: 1–56 years old Gender: 11F/26M | Retrospective | Laryngeal papillomatosis | NA | Complications: | carcinoma of larynx $n = 1/37$ | Number of operations per year does not correlate with eventual remission. |
| | | | | | Complications: | bronchial papillomata $n = 0/37$ | |
| | | | | | Remission | $n = 13/37 (35\%)$ | |

**Potassium titanyl phosphate (KTP) laser studies**

| Burns et al. (1990) | IV N/proc: 37/55 Age: 23–73 years old Gender: 16F/21M | Prospective uncontrolled | Recurrent laryngeal papillomatosis | 15 ms pulse width 5.25–7.5 J/pulse 2 Hz repetition rate 20–80 J/cm² fluence | Complications | $n = 0/51$ | $n = 28/35$ | KTP laser procedure is useful and safe for recurrent papillomatosis. Most patients had >90% of lesion regression at 4–12 weeks postoperation. |
| Hung et al. (2020) | IV N/proc: 16/79 Age: 23–73 years old Gender: 6F/10M | Prospective | Recurrent respiratory papillomatosis | 30–50 ms pulse width 7–8 W 2 Hz repetition rate | Complications | NA | VHI-10 |
| | | | | | | (1) Before operation | 28.3 |
| | | | | | | (2) After 1st operation | 12.0 |
| | | | | | | (3) After 2–5 repeated in-office or in-hospital procedures | 10.1 |
| | | | | | | (4) After 6–10 procedures | 11.0 |
| | | | | | | CPPs | (1) Before operation | 6.8 |
| | | | | | | | (2) After 1st operation | 10.5 |

However, using frequent laser treatment, a small number of severely affected children will require tracheotomy for incipient or overt respiratory obstruction.
| Authors (year) | EL Characteristics | Study type | Lesions | Laser settings | Outcomes | Results | Key findings |
|---------------|--------------------|------------|---------|----------------|----------|---------|-------------|
| Kaluskar et al. (2009) | IV | N/proc: 9/NA Age: 39–58 years old Gender: 2F/7M | Prospective uncontrolled | Inverted papilloma of the nose and paranasal sinuses | 8 W of power in continuous mode At least 80% calibration | Complications | $n = 0/9$ | KTP laser is a good option in view of the low rates of recurrence and the minimal postoperative morbidity |
| Wei et al. (2014) | IV | N/proc: 18/33 Age: 12–68 years old Gender: F3/M15 | Retrospective | Recurrence laryngeal papilloma | 6 W of power | Complications | $n = 0$ | KTP laser is safe and effective in the treatment of recurrent laryngeal papilloma. |
| Liu et al. (2005) | IV | N/proc: 22/NA Age: 3–60 years old Gender: NA | Retrospective | Laryngeal papilloma | NA | Complications | $n = 2/22$ | KTP laser treatment is less destructive, with high accuracy and precision, and good hemostatic effect. |
Therefore, balancing treatment for preoperative study. Consequently, a series of anti-viral drugs for instance, the meta-analysis of Rosenberg et al. 

Our recent studies have found that the number of surgeries/month significantly declined after long-term HPV vaccination compared with no vaccination. These adjuvant treatments may benefit patients with RRP treated with surgical excision and more studies are needed to assess the effects of combining KTP laser surgery with adjuvant therapies. In our review, we found that both KTP and CO2 laser groups demonstrated satisfactory outcomes for RRP in terms of cure rate. Nevertheless, the cure rate for the KTP laser (87.25%) was significantly higher than for the CO2 laser (75.98%), demonstrating that the main therapeutic effect of KTP laser was superior. In addition, though not significant, there was a relatively higher recurrence rate in the CO2 group (17.71%; p < .0001). It may appear that the overall recurrence rate was unexpectedly low, but this is due to the definition adopted for this parameter being re-occurrence within 1 year (see Section 2.4).

Another evaluation indicator was remission rate, of which the CO2 group was considerably lower than the KTP group (38.9% vs. 88.46%, p < .0001). For instance, HPV-6 and HPV-11 result in the low-risk and most common RRP infections, whereas HPV-16 and HPV-18 infections are high-risk but rarely occur. According to the clinical cases reviewed, there were two onset age categories. Juvenile onset RRP (JoRRP) represents patients whose RRP onset began before 12 years old, while AoRRP refers to patients whose RRP onset occurred after 12 years old. Most JoRRP is transmitted vertically during pregnancy or acquired from an infected mother at birth. As for AoRRP, it is often sexually transmitted, especially via oral sex.

Data indicate a trimodal distribution with peak RRP onset ages at seven, 35, and 64 years old. Despite this, researchers often find a bimodal distribution, which has been investigated for preventing and/or treating RRP, including the HPV vaccine, Interferon, Cidofovir, Bevacizumab, and Celecoxib, among others.

For instance, the meta-analysis of Rosenberg et al. found that the number of surgeries/month significantly declined after long-term HPV vaccination compared with no vaccination. These adjuvant treatments may benefit patients with RRP treated with surgical excision and more studies are needed to assess the effects of combining KTP laser surgery with adjuvant therapies.

In our review, we found that both KTP and CO2 laser groups demonstrated satisfactory outcomes for RRP in terms of cure rate. Nevertheless, the cure rate for the KTP laser (87.25%) was significantly higher than for the CO2 laser (75.98%), demonstrating that the main therapeutic effect of KTP laser was superior. In addition, though not significant, there was a relatively higher recurrence rate in the CO2 group than the KTP group (18.6% vs. 10.87%, p = .1595). It may appear that the overall recurrence rate was unexpectedly low, but this is due to the definition adopted for this parameter being re-occurrence within 1 year (see Section 2.4).

Another evaluation indicator was remission rate, of which the CO2 group was considerably lower than the KTP group (38.9% vs. 88.46%, p < .0001), while the HPV-detected and clearance rates were only reported in the CO2 group. Moreover, the safety outcome-complication rate of the KTP group (2.32%) was considerably lower than the CO2 group (17.71%; p < .0001). These findings indicate that the KTP laser can yield comparatively better outcomes than the CO2 laser for RRP treatment.

### Table 2: Preoperative study characteristics

| Outcome          | KTP laser | CO2 laser | p-Value* |
|------------------|-----------|-----------|----------|
| Age              | 49.83 ± 7.05b | 34.83 ± 7.36b | <.001    |
| Male             | 65.61% (292 of 445) | 66.25% (53 of 80) | >.05     |

*Between group KTP and group CO2. Bold indicates statistically significant.

### Table 3: Comparison of clinical outcomes. Not Reported (NR) refers to clinical outcomes that were not reported.

| Outcome          | KTP laser | CO2 laser | p-Value* |
|------------------|-----------|-----------|----------|
| Cure             | 87.25% (89 of 102) | 75.98% (389 of 512) | .0127    |
| Complications    | 2.33% (2 of 86) | 17.71% (88 of 497) | <.0001   |
| Recurrence       | 10.87% (10 of 92) | 18.63% (19 of 102) | .1595    |
| Remission        | 88.46% (46 of 52) | 38.90% (156 of 401) | <.0001   |
| HPV-detected     | NR        | 75.86% (22 of 29) |          |
| Clearance        | NR        | 9.88% (25 of 253) |          |

*Between group KTP and group CO2. Bold indicates statistically significant.

### 3.7 Risk of bias assessment

The MINORS scores of the five prospective cases in the KTP group averaged 13.1 (SD, 1.45; range, 11–15), suggesting a fair quality of studies (Supporting Information S3). Similarly, scores of the 10 prospective studies in the CO2 group averaged 13.6 (SD, 1.52; range, 12–15), also suggesting fair quality. No statistical difference existed between the MINORS scores of the two groups (p > .05).

### 4 Discussion

This systematic review assessed 15 clinical studies involving 614 RRP patients treated with CO2 or KTP laser excision. Of these, 2120 surgeries were performed on 102 KTP cases from 5 studies and 512 CO2 cases from 10 studies, separately. Both CO2 and KTP groups improved postoperatively in clinical outcomes. Nevertheless, compared with the CO2 group, the KTP group showed a significantly better cure rate and lower postoperative complications rate. To the best of our knowledge, this work is the first study that systematically and comprehensively compares the clinical outcomes of CO2 and KTP lasers for RRP. However, it should be noted that we found no study that directly compared CO2 and KTP laser treatment for RRP, so a meta-analysis approach could not be taken.

Although RRP is a benign disease, it is frequently associated with substantial morbidity and mortality. Therefore, balancing treatment goals (e.g., voice preservation and disease regression and/or restoration) with the morbidity and cost of treatment is necessary and should be seriously considered before treatment. Recent studies have found that HPV (a DNA virus) is the cause of RRP. Additional evidence suggests that more than 100 genotypes of HPV infection exist. For instance, HPV-6 and HPV-11 result in the low-risk and most common HPV infections, whereas HPV-16 and HPV-18 infections are high-risk but rarely occur. According to the clinical cases reviewed, there were two onset age categories. Juvenile onset RRP (JoRRP) represents patients whose RRP onset began before 12 years old, while AoRRP refers to patients whose RRP onset occurred after 12 years old. Most JoRRP is transmitted vertically during pregnancy or acquired from an infected mother at birth. As for AoRRP, it is often sexually transmitted, especially via oral sex.
According to the literature, several reasons may explain why the KTP laser is superior to the CO2 laser for treating RRP. The CO2 laser—quickly gained popularity for treating RRP since the 1960s. Many therapeutic options have also been advocated for RRP, such as microblade and PDL laser, but surgical removal using CO2 laser remains the most important single treatment choice available. Although the 10,600 nm wavelength of the CO2 laser is well absorbed by water in biological tissue and is suitable for fine surgical cutting, its application to remove laryngeal lesions is not without risk. Thermal injury, excessive resection, and repeated surgeries may result in a loss of pliable vocal fold tissue, fibrosis, and scar formation, which can significantly affect the voice and quality of life.

In contrast, KTP laser treatment has both the cutting function of the CO2 laser and the hemostatic effect of the PDL laser, so its application in laryngeal microsurgery has many advantages: (1) The operation is significantly less destructive than the traditional approach, without laryngeal laceration and with less tracheotomy ratio. In addition, KTP laser is more likely to preserve postoperative laryngeal function, and the postoperative hospital stays are shorter (meaning less cost), requiring only 2 or 3 days. (2) The accuracy and precision of surgery are improved by using a KTP laser. The tumor boundary can be clearly seen under the microscope, and the level of incision can be distinguished so that the lesion can be completely removed while minimizing collateral damage. (3) The fiber-based delivery of the KTP laser with the technical advancement of distal-tip endoscopy enables surgical procedures to be performed in office settings under local anesthesia, meaning that considerable time and medical expenses can be saved. Nevertheless, it should be noted that CO2 laser treatment has also been reported in a recent study to have been performed in an office setting. Thus, further studies should be conducted that specifically compare differences when the two lasers are used in an office setting to treat RRP. (4) The KTP laser has a good hemostatic effect and allows the surgery to be performed in a bloodless manner. Especially in children with laryngeal papilloma invading the supraglottis, tumors have rich blood supplies. Thus, under these conditions, the KTP laser can be applied to great advantage, resulting in a clearer field and a well-defined incision, reducing collateral damage. Nevertheless, despite the abovementioned advantages of KTP, there is still a major limitation on its adoption and widespread use, namely that KTP laser equipment is relatively more expensive than CO2 lasers.

Our review has several limitations that should be mentioned. First, the available studies and data about KTP laser used for RRP were very limited (102 patients). The case number only achieved the minimal sample number after conducting a sample size estimation (58 in each group). Second, much data reported by different studies were not consistent between the KTP and CO2 groups. For example, the HPV positive and clearance rates for RRP were always presented in the CO2 group but rarely appeared in the KTP group, making it impossible to compare those parameters and potentially influencing the results of this study. We, therefore, recommend that future studies report these data for patients with RRP whenever possible. In addition, the age difference (before surgery) between the CO2 group and KTP group should be noted. That being said, we believe that due to the way most studies in the CO2 group did not report the detailed ages of patients (419/510 patients), the age data from the two groups were not entirely representative, so the difference is not likely to be a serious problem. Furthermore, most studies did not clearly report their follow-up times, which may result in unavoidable heterogeneity in parameters such as cure rate. Third, high-quality comparative evidence is noticeably insufficient as most studies meeting our inclusion criteria were at level IV. Nevertheless, the MINORS scores of these studies averaged 13.1 and 13.6 in the CO2 and KTP groups, respectively, demonstrating the evidence was of fair quality. Future research is necessary in the form of standard-evaluation prospective multicenter randomized controlled studies. Fourth, key functional parameters such as vocal outcomes were not reported in sufficient detail in the available studies, limiting the safety outcome only to complications. Future studies should take care to clearly report these data whenever possible.

5 | CONCLUSION

This systematic review demonstrated that the clinical outcomes of KTP laser and CO2 laser were good for treating RRP. However, overall, our findings indicate that KTP laser may be a good treatment option with superior outcome and lower postoperative complication rates than CO2.
laser treatment (Figure 2). In the future, more high-quality randomized controlled studies on the long-term outcomes of these two techniques are needed to further evaluate them, especially study designs that directly compare the two laser treatment approaches. Studies must also provide all relevant pre- and postoperative functional parameters.

ACKNOWLEDGMENT

The authors would like to thank Dr. Zhiwen Luo for providing critical support and expertise in preparing this manuscript.

FUNDING INFORMATION

This study did not receive any specific funding from agencies in the public, private, or not-for-profit sectors.

CONFLICT OF INTEREST

The authors declare no conflicts of interest.

DATA AVAILABILITY STATEMENT

All data that support the findings of this work are available upon request to the corresponding author.

ORCID

Jimin Yang https://orcid.org/0000-0003-0484-6639
Zhongcheng Xie https://orcid.org/0000-0001-9070-9088
Barnabas C. Seyler https://orcid.org/0000-0002-4823-8793

REFERENCES

1. Gutiérrez Castillo C, Monerris García E, Duran MD, Sancho Mestre M, Gras JR. Papilomas y papilomatosis laringea. Tratamiento con láser CO₂. Nuestra experiencia en 15 años. Acta Otorrinolaringol Esp. 2010; 61(6):422-427. doi: 10.3101/jotorri.2010.07.006
2. Kim HT, Baizhumanova AS. Is recurrent respiratory papillomatosis a manageable or curable disease? Laryngoscope. 2016;126(6):1359-1364. doi: 10.1002/lary.25795
3. Maturo SC, Hartnick CJ, Maturo SC, Hartnick CJ. Juvenile-onset recurrent respiratory papillomatosis. Pediatr Airway Surg. 2012;73:105-108. doi: 10.1159/000334457
4. Valerie A, Vasiliki KE. Recurrent respiratory papillomatosis: an extensive review. Int J Hematol Stem Cell Res. 2012;6(3):19-28. http://ijhscr.tums.ac.ir/index.php/ijhscr/article/view/312/325
5. Ivancic R, Iqbal H, deSilva B, Pan Q, Matrka L. Current and future management of recurrent respiratory papillomatosis. Laryngoscope Investig Otolaryngol. 2018;3(1):22-34. doi: 10.1002/litc.132
6. Kurita T, Chitose S-I, Sato K, et al. Pathological mechanisms of laryngeal papillomatosis based on laryngeal epithelial characteristics. Laryngoscope Investig Otolaryngol. 2019;4(1):89-94. doi: 10.1002/litc.2242
7. Kim D, Siegel J, Chouake RJ, et al. Implication and management of incidental oropharyngeal papillomas—a retrospective case series review. Ear Nose Throat J. 2019;100(4):145561319871228. 10.1177/0145561319899183
8. Wiattrak BJ. Overview of recurrent respiratory papillomatosis. Curr Opin Otolaryngol Head Neck Surg. 2003;11(6):433-441. doi: 10.1097/00002084-200312000-00005
9. Lechien JR, Burns JA, Akst LM. The use of 532-nanometer-pulsed potassium-titanyl-phosphate (ktp) laser in laryngology: a systematic review of current indications, safety, and voice outcomes. Ear Nose Throat J. 2020;100(1):45-13S. doi: 10.1177/0145561319899183
10. Wei C, Zhang P, Peijie He KK. KTP laser treatment for recurrent laryngeal papilloma. 13th Natl Acad Conf Otolaryngol Neck Surg Chinese Med Assoc. 2014;202-203.
11. Dodhia S, Baxter PC, Ye F, et al. Investigation of the presence of HPV on KTP laser fibers following KTP laser treatment of papilloma. Laryngoscope. 2018;128(4):926-928. doi: 10.1002/lary.27018
12. Florian Preuss S, Peter Klussmann J, Junghelusing M, Edmund Eckel H, Guntinas-Lichius O, Damm M. Long-term results of surgical treatment for recurrent respiratory papillomatosis. Acta Otolaryngol. 2007;127(11):1196-1201. doi: 10.1080/004807010200350
13. Toma S, Hudson K, Harriess M. Abstracts of the 14th British Academic Conference in Otolaryngology Posters—laryngology. Clin Otolaryngol. 2012;37(suppl 1):118-129. doi: 10.1111/j.1749-4486.2012.02513.x
14. Motta G, Villari G, Pucci V, De Clemente M. CO₂ laser in laryngeal microsurgery. Int Surg. 1987;72(3):175-178. http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed3&NEWS=N&AN=18673423
15. Pratt LW. The CO₂ laser in otolaryngology. J Med Assoc. 1980;71(2):39-45. http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed3&NEWS=N&AN=10530249
16. Damm M, Eckel HE, Schneider D, Arnold G. CO₂ laser surgery for verrucous carcinoma of the larynx. Lasers Surg Med. 1997;21(2):117-123. doi: 10.1002/slc.510019972123.0.CO;2-T
17. Keane WM, Atkins JP. CO₂ laser surgery of the upper airway. Surg Clin North Am. 1984;64(1):955-971. doi: 10.1016/S0039-6109(16)43439-0
18. Wellenstein DJ, Honings J, Schimberg AS, et al. Office-based CO₂ laser surgery for benign and premalignant laryngeal lesions. Laryngoscope. 2020;130(6):1503-1507. doi: 10.1002/lary.28278
19. Strong MS, Vaughan CW, Cooperband SR, Healy GB, Clemente MA. Recurrent respiratory papillomatosis. Management with the CO₂ laser. Ann Otol Rhinol Laryngol. 1976;85(4):509-516. http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed3&NEWS=N&AN=7146817
20. McMillan K, Shapshay SM, McGilligan JA, Wang Z, Rebeiz EE. Preliminary clinical results of pulsed dye laser therapy for recurrent respiratory papillomatosis. In: Anderson RR, Bartels KE, Bass LS, et al., eds. Lasers in Surgery: Advanced Characterization, Therapeutics, and Systems VIII. Proceedings of Vol 3245: Proceedings of the Society of Photo-Optical Instrumentation Engineers. SPIE; 1998:182-190. doi: 10.1117/12.312286
21. Valdez TA, McMillan K, Shapshay SM. A new laser treatment for vocal cord papilloma—585-nm pulsed dye. Otolaryngol Head Neck Surg. 2001;124(4):421-425. doi: 10.1067/mhn.2001.113944
22. McMillan K, Shapshay SM, McGilligan JA, et al. A 585-nanometer pulsed dye laser treatment of laryngeal papillomas: preliminary report. Laryngoscope. 1998;108(7):968-972. doi: 10.1097/00005537-199807000-00003
23. Abitol J, Abitol P. Pulse dye laser: laryngeal microsurgical procedure by non-invasive laser surgery on outpatients about 57 cases. Lasers Surg Med. 2013;45(suppl 25):67-68. doi: 10.1002/lsm.22127
24. Snoeck W, Wellens W, Desloovere C, et al. Treatment of severe laryngeal papillomatosis with intralesional injections of cidofovir [(S)-1-(3-hydroxy-2-phosphonylmethoxycarbonyl)cytosine]. J Med Virol. 1998;54(3):219-225. doi: 10.1002/00005537.199805219.00003
25. Coulombeau B, Nusa Naiman A, Ceruse P, Froehlich P. Anti-viral injectable treatment (cidofovir) in laryngeal papillomatosis. Rev Laryngol Otol Rhinol (Bord). 2002;123(5):315-320.
26. Chhetri DK, Blumin JM, Shapiro NL, Berke GS. Office-based treatment of laryngeal papillomatosis with percutaneous injection of cidofovir. Otolaryngol Head Neck Surg. 2002;126(6):642-648. doi: 10.1067/mhn.2002.125604
27. Kaufman J. Office-based 532-nm pulsed KTP laser treatment of glottal papillomatosis and dysplasia. Ann Otol Rhinol Laryngol. 2007;116(4):317. http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed3&NEWS=N&AN=46821157
er bi yan hou jing wai ke za zhi = J Clin Otorhinolaryngol Head Neck Surg. 2015;29(21):1873-1877. http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed11&NEWS=N&AN=611139790
47. Best SR, Esquivel D, Mellinger-Pilgrim R, et al. Infectivity of murine papillomavirus in the surgical byproducts of treated tail warts. Laryngoscope. 2020;130(3):712-717. doi:10.1002/lary.28026
48. Best SR, Esquivel D, Mellinger-Pilgrim R, RBS R, Pitman MJ. Nasopharyngeal papillomas treated with CO2 laser and human papillomavirus vaccination. Laryngoscope. 2017;127(10):2279-2281. doi:10.1002/lary.26580
49. Ilmarinen T, Auvinen E, Hiltunen-Back E, Ranki A, Aitlonen LM, Pitkäranta A. Transmission of human papillomavirus DNA from patient to surgical masks, gloves and oral mucosa of medical personnel during treatment of laryngeal papillomas and genital warts. Eur Arch Oto-Rhino-Laryngol. 2012;269(11):2367-2371. doi:10.1007/s00405-012-2049-9
50. Snoeck R, Wellens W, Desloovere C, et al. Laryngeal papillomatosis: clinical, histopathologic and molecular studies. Clin Otolaryngol. 2015;113(3):221-224. doi:10.1177/14452197.2017.00010
51. Fortes HR, van Ranke FM, Eschissato DL, et al. Recurrent respiratory papillomatosis: a state-of-the-art review. Respir Med. 2017;126:116-121. doi:10.1016/j.rmed.2017.03.030
52. San Giorgi MRM, van den Heuvel ER, Tjon Pian Gi REA, et al. Age of onset of recurrent respiratory papillomatosis: a distribution analysis. Clin Otolaryngol. 2016;41(5):448-453. doi:10.1111/doi.12565
53. Maiga S, Ndlate M, Diouf MS, et al. Laryngeal papillomatosis in Senegal: a ten-year experience. Eur Ann Otorhinolaryngol Neck Dis. 2018;135(3):221-224. doi:10.1016/j.anorl.2018.01.002
54. Kim Cho Eon P, Schulte L, Sudhoff H. Recurrent respiratory papillomatosis (RPP)-time for a reckoning? Laryngoscope Investig Otolaryngol. 2017;2(4):184-186. doi:10.1002/lio2.80
55. Tu Y-P, Jennings R, Hart B, et al. Therapeutic use of the HPV vaccine on recurrent respiratory papillomatosis: a systematic review and meta-analysis. Rosenberg. J Gerontol Ser A Biol Sci Med Sci. 2018;0813(April):1-11.
56. Scatolini ML, Labedz G, Cocciglacia A, et al. Laryngeal sequelae secondary to surgical treatment for recurrent respiratory papillomatosis in children. Int J Pediatr Otorhinolaryngol. 2020;130:109815. doi:10.1016/j.ijpedit.2019.109815
57. Nielsen NR, Rasmussen N. Laryngeal papillomatosis treated with CO2 laser. Ugeskr Laeger. 2010;172(4):284-289. http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed11&NEWS=N&AN=358579361
58. Hulkm SL, Moberly AC. Patient tolerance of the flexible CO2 laser for office-based laryngeal surgery. J Voice. 2010;24(6):750-754. doi:10.1016/j.jvoice.2009.04.005
59. Hirano M, Clinical examination of voice by Minoru Hirano. J Acoust Soc Am. 1986;80(4):1273
60. Kaufman J, Zeitels SM, Akst LM, et al. Office-based 532 nm pulsed KTP laser treatment of glottal papillomatosis and dysplasia. Ann Otol Rhinol Laryngol. 2006;115(9):679-685. doi:10.1177/000348940611500905

SUPPORTING INFORMATION
Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Yang J, Xie Z, Seyler BC. Comparing KTP and CO2 laser excision for recurrent respiratory papillomatosis: A systematic review. Laryngoscope Investigative Otolaryngology. 2022;7(4):970-981. doi:10.1002/lio2.871